NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology
Jackson Center, PA, August 04, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association (NFL RPA), for Halberd’s research work in the development of treatments for Traumatic Brain Injury (TBI)/chronic traumatic encephalopathy (CTE) sustained by current and retired players. Traumatic brain injuries often progress to neurodegenerative diseases, such as PTSD, Alzheimer’s Disease, Parkinson’s Disease, Epilepsy and suicide ideation. The letter of endorsement ...
Halberd Corp. Launches “Halberd Cancer Therapeutics, LTD” Wholly Owned Subsidiary
Jackson Center, PA, July 20, 2022 – Halberd Corporation (OTC-PINK: "HALB”) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd’s patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses. For now, the new entity will be staffed by Halberd personnel until such time as business opportunities arise and appropriately skilled individuals are recruited to carry the subsidiary forward in its ...
Halberd’s Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron
Boosts Effectiveness of Commercial Covid Antibodies by 45% Jackson Center, PA, July 14, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in circulation, including Omicron. When Halberd’s antibody was combined with a leading commercially available Covid-19 antibody in an antibody cocktail, effectiveness of the commercial antibody was increased from 65% to 94%. This could lead to a treatment that is widely effective ...
Halberd Corporation Update, CEO Letter and 2022 Expectations
Q2 Accomplishments and a Look to the Future Jackson Center, PA, July 12, 2022. Halberd Corporation (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. The accomplishments for the Second Quarter ending June 30, 2022, are as follows: 2Q ACHIEVEMENTS Added an animal testing expert (DVM/PhD) to our list of scientific consultants to plan and execute extensive animal testing of Halberd’s patented extracorporeal process for the ...
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer
Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC-PINK: "HALB”) announced the creation of a subgroup of researchers to focus on cancer treatment. Halberd’s technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments. The subgroup will be guided by Halberd’s existing technical team members, but will add the necessary expertise to carry the program forward without diluting its ...
Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification
Jackson Center, PA, June 8, 2022 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd’s patented extracorporeal disease eradication processes. Consistent with its press release of May 18, 2022, Halberd commenced its pursuits with mdi Consultants, Inc, an FDA application consulting firm, and the FDA to determine specific animal testing requirements. Animal testing will be ...